Main contents starts here
Press Releases 2010
- July 30, 2010
Takeda Announces the Appointment of Executive Vice President, International Operations (Americas/Europe) and Senior Vice President, International Operations (Asia), the establishment of new organization - July 30, 2010
Takeda Expands International Operations Leadership - July 23, 2010
Approval of an Additional Indication of “Takepron® Capsules 15” and “Takepron® OD Tablets 15” in Japan for Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer during Low-dose Aspirin Administration - July 16, 2010
Approval of Lampion® Pack in Japan for Secondary Eradication of Helicobacter pylori - July 12, 2010
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - July 9, 2010
Takeda Included in the FTSE4Good Global Index for the Sixth Consecutive Year - July 6, 2010
Launches of “ROZEREM®” for treatment of insomnia, “METACT®” for treatment of type 2 diabetes and Actos® Orally Disintegrating Tablets for treatment of type 2 diabetes in Japan - June 29, 2010
AMAG Pharmaceuticals and Takeda Announce Acceptance of Submission of Feraheme® Marketing Authorization Application to the European Medicines Agency and Initiation of Global Registrational Program for Feraheme for the Treatment of Iron Deficiency Anemia - June 28, 2010
Takeda Appoints Two Executive-level Personnel from Outside the Company - June 28, 2010
Takeda Announces Appointment of New Executive and Corporate Officer - June 25, 2010
Takeda Announces Appointment of New Corporate Officers - June 25, 2010
Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors - June 23, 2010
Takeda to Expand Presence in Asia with Operations in South Korea - June 22, 2010
ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
First and only fixed-dose combination oral antidiabetic medication with extended-release metformin available in once-daily dosing - June 21, 2010
AFFYMAX AND TAKEDA ANNOUNCE PHASE 3 TRIALS MEET PRIMARY ENDPOINTS FOR INVESTIGATIONAL DRUG, HEMATIDE™/PEGINESATIDE, TO TREAT ANEMIA IN CHRONIC RENAL FAILURE WITH SOME DIFFERENCES NOTED IN SECONDARY ANALYSES - June 18, 2010
Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors - June 17, 2010
CanBas and Takeda to Terminate Collaboration for CBP501 for the Treatment of Cancer - June 15, 2010
Launches of “NESINA®” for treatment of type 2 diabetes, “UNISIA®” for treatment of hypertension and “Vectibix®”, anti-cancer agent, in Japan - June 2, 2010
Takeda Achieves Zero Emissions at its Plants in Japan - May 21, 2010
Takeda Announces Change in Management with the Establishment of New Organization - May 12, 2010
2010-2012 Mid-Range Plan Transformation for a New Takeda - May 10, 2010
Takeda to Co-promote VELCADE® (bortezomib) for Injection in Japan
--Takeda continues to build global presence in oncology-- - May 7, 2010
Announcement regarding Establishment of Sponsored ADR Program - April 28, 2010
Takeda Provides Update on Patent Litigation for ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the U.S.
Takeda Announces Assumption for FY 2010 Financial Outlook and Mid-Range Plan - April 28, 2010
Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension - April 16, 2010
New Drug Applications Approval for Five New Products in Japan - April 13, 2010
Takeda’s Annual Report 2009 and CSR Data Book 2009 receive third prize in Sustainability Reporting Award - April 8, 2010
Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma
-AETHERA trial designed to support full approval in the United States and Europe-
-Data from ongoing pivotal trial to be reported in second half of 2010 and provide basis for NDA and MAA submissions in the first half of 2011 - - April 1, 2010
AMAG Pharmaceuticals and Takeda Pharmaceutical Company Announce Strategic Collaboration for Feraheme® in All Therapeutic Indications in Select Ex-US Territories, Including Europe - April 1, 2010
About Agreement Reached to Co-market R113675 (Galantamine Hydrobromide), a Treatment for Alzheimer’s Disease - March 25, 2010
Takeda Submits Application in Japan for Additional Indications of Alogliptin for Combination Therapy with Sulfonylurea and Combination Therapy with Biguanide - March 19, 2010
Takeda Announces Withdrawal of Marketing Authorization Application for a Prolonged-Release Formulation of Competact® and discontinuation of its development in the EU - March 18, 2010
Takeda Launches Initiative for Capacity Development of Health Care Workers in Africa through programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria - March 16, 2010
A Once-Monthly Formulation of Risedronate Sodium Hydrate for the Treatment of Osteoporosis Entered Into Phase 3 Clinical Programs in Japan - March 5, 2010
KAPIDEX™ (dexlansoprazole) Renamed DEXILANT™ in U.S. to Avoid Name Confusion - March 3, 2010
Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 - February 23, 2010
Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Phase 2 Extension Study Demonstrated Sustained Weight Loss - February 18, 2010
HEMATIDE™ ENTERED INTO THE PHASE 3 CLINICAL PROGRAM TO TREAT ANEMIA IN CHRONIC RENAL FAILURE PATIENTS IN JAPAN - February 1, 2010
FIRST TREATMENT TO IMPROVE SURVIVAL IN 20 YEARS NOW AVAILABLE FOR PATIENTS WITH OSTEOSARCOMA (BONE CANCER) - January 18, 2010
Approval of Actos® Orally Disintegrating Tablets in Japan